BioLineRx (BLRX) Change in Receivables (2014 - 2025)

BioLineRx's (BLRX) quarterly Change in Receivables came in at -$46000.0 in Q4 2025, down 104.05% year-on-year from $1.1 million in Q4 2024, and down 158.97% quarter-over-quarter from $78000.0 in Q3 2025.

BioLineRx (BLRX) Change in Receivables (2014 - 2025) Analysis & Trends

BioLineRx's Change in Receivables history runs 4 years deep, the most recent figure standing at -$46000.0 for Q4 2025.

  • On a quarterly basis, Change in Receivables fell 104.05% year-over-year to -$46000.0 in Q4 2025; TTM through Dec 2025 was $2.4 million, a 214.73% increase from a year earlier, with the FY2025 full-year figure at $2.4 million, up 214.73% from the prior year.
  • Change in Receivables eased to -$46000.0 in Q4 2025 per BLRX's latest filing, from $78000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $1.4 million in Q2 2025 and bottomed at -$2.5 million in Q1 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Receivables (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 75.30 Mn
4 NuCana 279.75 Bn 279.75 Bn - 2.84 Mn
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -39.80 Mn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -1.20 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 BioLineRx 7.05 Bn 7.06 Bn 154,000.00 -46,000.00

Historic Data

Download Data
DateValue
Dec 31, 2025 -46,000.00
Dec 31, 2025 -46,000.00
Sep 30, 2025 78,000.00
Sep 30, 2025 78,000.00
Jun 30, 2025 1.39 Mn
Jun 30, 2025 1.39 Mn
Mar 31, 2025 1.01 Mn
Mar 31, 2025 1.01 Mn
Dec 31, 2024 1.14 Mn
Dec 31, 2024 1.14 Mn
Sep 30, 2024 -432,000.00
Sep 30, 2024 -432,000.00
Jun 30, 2024 -347,000.00
Jun 30, 2024 -347,000.00
Mar 31, 2024 -2.47 Mn
Mar 31, 2024 -2.47 Mn
Dec 31, 2015 658,000.00
Dec 31, 2015 658,000.00
Sep 30, 2015 -275,000.00
Sep 30, 2015 -275,000.00